Long non-coding RNA(lncRNA) can interact with microRNA(miRNA) and play an important role in inhibiting or activating the expression of target genes and the occurrence and development of tumors. Accumulating studies focus on the prediction of miRNA-lncRNA interaction, and mostly are concerned with biological experiments and machine learning methods. These methods are found with long cycles, high costs, and requiring over much human intervention. In this paper, a data-driven hierarchical deep learning framework was proposed, which was composed of a capsule network, an independent recurrent neural network with attention mechanism and bi-directional long short-term memory network. This framework combines the advantages of different networks, uses multiple sequencederived features of the original sequence and features of secondary structure to mine the dependency between features, and devotes to obtain better results. In the experiment, five-fold cross-validation was used to evaluate the performance of the model, and the zea mays data set was compared with the different model to obtain better classification effect. In addition, sorghum, brachypodium distachyon and bryophyte data sets were used to test the model, and the accuracy reached 0.9850, 0.9859 and 0.9777, respectively, which verified the model's good generalization ability.

RNA binding protein (RBP) is extensively involved in various cellular regulatory processes through the interaction with RNAs. Capturing the RBP binding preferences is fundamental for revealing the pathogenesis of complex diseases. Many experimental detection techniques are still time-consuming and labor-intensive, therefore, it is indispensable to develop a computational method with convincing accuracy. In this study, we proposed a CNN-BLSTM hybrid deep learning framework, named DeepDW, for predicting the RBP binding sites on RNAs with high-order encoding features of RNA sequence and secondary structure. The high-order encoding strategy was used to characterize the dependencies among adjacency nucleotides. For CNN-BLSTM hybrid model, DeepDW first employed two 1-D convolutional neural networks (CNNs) for learning the local features from high-order encoded matrices of RNA sequence and structure separately, and then applied two bidirectional long short-term memory networks (BLSTMs) to capture the global information in a higher level. Moreover, a series of experiments were carried out on 31 public datasets to evaluate our proposed framework, and DeepDW achieved superior performance than the state-of-the-art methods. The results indicated that the combination of high-order encoding method and CNN-BLSTM hybrid model had advantages in identifying RBP-RNA binding sites.

Predicting potential drug-disease associations (RDAs) plays a pivotal role in elucidating therapeutic strategies for diseases and facilitating drug repositioning, making it of paramount importance. However, existing methods are constrained and rely heavily on limited domain-specific knowledge, impeding their ability to effectively predict candidate associations between drugs and diseases. Moreover, the simplistic definition of unknown information pertaining to drug-disease relationships as negative samples presents inherent limitations. To overcome these challenges, we introduce a novel hierarchical negative sampling-based graph contrastive model, termed HSGCLRDA, which aims to forecast latent associations between drugs and diseases. In this study, HSGCLRDA integrates the association information as well as similarity between drugs, diseases and proteins. Meanwhile, the model constructs a drug-disease-protein heterogeneous network. Subsequently, employing a hierarchical structural sampling technique, we establish reliable negative drug-disease samples utilizing PageRank algorithms. Utilizing meta-path aggregation within the heterogeneous network, we derive low-dimensional representations for drugs and diseases, thereby constructing global and local feature graphs that capture their interactions comprehensively. To obtain representation information, we adopt a self-supervised graph contrastive approach that leverages graph convolutional networks (GCNs) and second-order GCNs to extract feature graph information. Furthermore, we integrate a contrastive cost function derived from the cross-entropy cost function, facilitating holistic model optimization. Experimental results obtained from benchmark datasets not only showcase the superior performance of HSGCLRDA compared to various baseline methods in predicting RDAs but also emphasize its practical utility in identifying novel potential diseases associated with existing drugs through meticulous case studies.

Recent studies have found that lncRNA (long non-coding RNA) in ncRNA (non-coding RNA) is not only involved in many biological processes, but also abnormally expressed in many complex diseases. Identification of lncRNA-disease associations accurately is of great significance for understanding the function of lncRNA and disease mechanism. In this paper, a deep learning framework consisting of stacked autoencoder(SAE), multi-scale ResNet and stacked ensemble module, named DHNLDA, was constructed to predict lncRNA-disease associations, which integrates multiple biological data sources and constructing feature matrices. Among them, the biological data including the similarity and the interaction of lncRNAs, diseases and miRNAs are integrated. The feature matrices are obtained by node2vec embedding and feature extraction respectively. Then, the SAE and the multi-scale ResNet are used to learn the complementary information between nodes, and the high-level features of node attributes are obtained. Finally, the fusion of high-level feature is input into the stacked ensemble module to obtain the prediction results of lncRNA-disease associations. The experimental results of five-fold cross-validation show that the AUC of DHNLDA reaches 0.975 better than the existing methods. Case studies of stomach cancer, breast cancer and lung cancer have shown the great ability of DHNLDA to discover the potential lncRNA-disease associations.